Pseudotype Production Optimization

描述(由申请人提供)： ViraCore是一家以工具为基础的生物技术公司，正在创建一个供制药和生物技术行业使用的药物发现平台。ViraCore正在开发“脂粒”，即被脂质双层包围并嵌入膜结合受体的纳米颗粒，以提纯和溶解细胞表面的复杂受体，同时保持它们的结构完整性。ViraCore打算利用这项技术在生物传感器和其他微流控设备上发现和研究完整的膜蛋白。目前使用的药物中约有一半针对膜蛋白，包括G蛋白偶联受体。这项建议的目的是扩大脂类制品的生产技术，修改和改进脂类制品的性质，开始开发具有独特功能的第二代脂类制品，并验证脂类制品在药物发现应用中的有效性。这项建议的目标是：-优化商业制造方案-开发第二代脂肪制品-改善脂肪制品的成分-验证脂肪制品作为药物筛选试剂

DESCRIPTION (provided by applicant): ViraCore is a tool-based biotechnology company that is creating a drug discovery platform for use by the pharmaceutical and biotechnology industries. ViraCore is developing "lipoparticles", nanometer-sized particles surrounded by a lipid bilayer and embedded with membrane-bound receptors, to purify and solubilize complex receptors from the cell surface while maintaining their structural integrity. ViraCore intends to leverage this technology for drug discovery and research of integral membrane proteins on biosensors and other microfluidic devices. Approximately half of the drugs in use today target membrane proteins, including G-protein coupled receptors. The purpose of this proposal is to scale lipoparticle production techniques, modify and improve lipoparticle properties, begin development of second-generation lipoparticles with unique capabilities, and validate lipoparticles for drug discovery applications. The goals of this proposal are to: - Optimize Commercial Manufacture Protocols - Develop Second- generation Lipoparticles - Improve Lipoparticle Composition - Validate Lipoparticles as Drug Screening Reagents